


PHARMACEUTICAL 2019

RVL Pharmaceuticals plc Rank 189 of 363







PHARMACEUTICAL 2019

RVL Pharmaceuticals plc Rank 189 of 363



The relative strengths and weaknesses of RVL Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RVL Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 178% points. The greatest weakness of RVL Pharmaceuticals plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 92%, being 55% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	172,385
Cost of Goods Sold	135,014
Intangible Assets	591,245
Liabilities, Current	114,394
Liabilities, Non-Current	266,803
Other Assets	752
Other Compr. Net Income	-1,213
Other Expenses	94,953
Other Liabilities	28,179
Other Net Income	-20,126
Other Revenues	263,701
Property and Equipment	31,263
Research and Development	48,761
Selling, General and Administrative Expense	74,243

Output Variable	Value in 1000 USD
Assets	795,645
Liabilities	409,376
Expenses	352,971
Revenues	263,701
Stockholders Equity	386,269
Net Income	-109,396
Comprehensive Net Income	-110,003
Economic Capital Ratio	92%

